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Background: Epstein–Barr virus (EBV) is a primary cause of infectious mononucleosis (IM) throughout the world,
and the positive serology rate changes over time in infected individuals. The aim of this study was to explore the
serological and clinical features among Chinese children with EBV infections. A retrospective study of children
suspected of having IM was conducted. Peripheral blood samples were analyzed by indirect immunofluorescence
to detect any EBV-specific antibodies. Samples were classed as positive (+) or negative (−) to immunoglobulins M
(IgM) or G (IgG) to the viral capsid antigen (VCA) or EBV nuclear antigen (EBNA). A standard medical history was
taken, including epidemiological data and noting any clinical manifestations.
Results: Of 317 children, 37 were aged <8 months; 10 of these were VCA-IgM+, and the youngest was aged 1
month; 280 were aged >8 months. The EBV infection rate ranged from 21.4% among subjects aged 8–12 months
to 84.2% in those aged >9 years. Serologically, children who tested as VCA-IgM+ together with VCA-IgG and EBNA-
IgG– had longer hospital stays with more palatal petechiae and lymphadenopathy, especially among those with an
atypical lymphocyte count of >10%. Children with the serological patterns [VCA-IgM–, VCA-IgG+ and EBNA-IgG–]
and [VCA-IgM+ VCA-IgG+ and EBNA-IgG+] did not show specific clinical features.
Conclusions: Infants aged <8 months could be infected with EBV. About 84% of these Chinese children aged >9
years had serological evidence of EBV infection, whereas IM peaked in patients aged 2–3 years.
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Epstein–Barr virus (EBV), a member of the herpesvirus fam-
ily, is one of the primary causes of infectious mononucleosis
(IM) in children and teenagers, and is widespread through-
out the world. Following primary infection, the virus estab-
lishes lifelong latency, and more than 90% of adults today
have serological evidence of past infections [1,2].
The indirect immunofluorescence assay (IFA) is widely
used for the routine evaluation of EBV immunological sta-
tus [3-5]. Although the EBV genome encodes many struc-
tural and nonstructural genes, those of most importance
for serodiagnosis are the genes encoding the viral capsid
antigens (VCAs), the early antigens (EAs) and the virus* Correspondence: zhaodong@public.wh.hb.cn
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reproduction in any medium, provided the ornuclear antigens (EBNAs). Four serological parameters are
essential for detecting EBV-specific immunoglobulin M
(IgM) or immunoglobulin G (IgG) antibodies in immuno-
competent individuals on a qualitative basis: IgM-VCA,
VCA-IgG, EA-IgG and EBNA-IgG. VCA-IgM is generally
designated as an indicator of a recent primary infection
[2]. Nevertheless, VCA-IgM might appear later, or might
be produced only transiently, or might persist at such a
low concentration as to be missed by laboratory tests and
the low and high affinity IgG have different significance
during EBV infection, low affinity anti-VCA IgG suggests
a early stage infection and high anti-VCA IgG suggests
post infection[6]. In addition, some patients do not pro-
duce EBNA-1-IgG [7], and even if this antibody is gener-
ated, it can disappear, especially among patients with
immunosuppression [8,9]. Therefore, the routine addition
of an estimation of anti-VCA-IgG avidity to diagnosticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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EBNA-IgG– and low-avidity VCA-IgG+ has excellent sen-
sitivity and specificity [4,10].
EBV seropositivity among children has much geographic
variation. The positive rate is much higher among children
in Asia than those in Western countries [11-14]. This
study aimed to explore serological outcomes and clinical
features in children with EBV infection and to interpret
the implications.
Methods
A total of 317 inpatients (197 boys and 120 girls), with
ages ranging from 1 to 164 months, were enrolled for
this retrospective study. All were admitted to Zhongnan
Hospital of Wuhan University, P. R. China, between July
2008 and August 2010, suspected of having IM. They
had one of the following signs: (1) at least three of the
EBV-related symptoms of fever, rash, lymphadenopathy,
pharyngitis, palatal petechiae, hepatomegaly, or spleno-
megaly; (2) fever lasting longer than five days; (3) re-
spiratory tract infection symptoms lasting longer than
five days and unresponsive to conventional antibiotic
treatment. Children with EBV-associated malignant dis-
eases such as malignant lymphoma or chronic active
EBV infection were excluded.
Informed consent was obtained from each patient par-
ent at the time that serum samples were collected for
assessing EBV antibody status. The study was approved by
the Ethics Committee of Wuhan University Zhongnan
Hospital, in accordance with the Helsinki Declaration.
Definition of EBV infection
A primary infection was defined as the presence of VCA-
IgM, or positive assays for EA-IgG or low-affinity anti-
VCA-IgG. Past infection was defined as a positive assay for
IgG to VCA and IgG to EBNA, or the detection of high-
affinity anti-VCA-IgG without VCA-IgM or EA-IgG.Table 1 EBV antibody combinations in EBV-positive patients
VCA-IgM Low affinity VCA-IgG EBNA-IgG EA-IgG
+ – – – –
+ – – + –
+ + – + –
+ + + + +
– + + + –
– + + – +
– – + + +
– – + + –
– – + – –
– – – + –
– – – – –Uninfected children were defined as having no detectable
antibodies to EBV. Peripheral blood samples were obtained
from all children within 24 h after admission to the
pediatric department. Specific antibodies to EBV were
detected using a commercial indirect immunofluorescence
(IIF) kit IFA (EUROIMMUN, Lübeck, Germany) following
the manufacturer’s instructions [10,15,16]. The diagnosis of
IM based on Sumaya criteria [17].
Statistical analysis
Data are presented as the percentage or mean ± stand-
ard deviation (SD). All statistical analyses were per-
formed using SPSS software (version 16; SPSS Inc.,
Chicago, IL, USA). The chi-squared test was used to
compare between-group differences in percentages. The
rank–sum test was used to compare differences between
the dates of measurements, and P < 0.05 was accepted
as statistically significant.
Results
Serological features of EBV antibodies
Of 317 patients, 37 children were aged <8 months: 27
boys and 10 girls. The EBV antibody patterns are shown
in Table 1. The serological pattern [VCA-IgM–, VCA-
IgG and EBNA-IgG+] was the most common combin-
ation. Three patients aged 5, 6 and 7 months had the
pattern [VCA-IgM+, VCA-IgG and EBNA-IgG–]. The
youngest child with a primary infection was only 1
month old. There were 280 children aged ≥8 months:
170 boys and 110 girls. The seropositive patterns
included 95 (33.9%) with a past infection, 60 (21.4%)
with a primary infection and 9 (3.2%) with orphaned
VCA-IgG+ (Table 2).
The distribution of antibodies by age is presented in
Figure 1. The trends in the age distribution of VCA-IgG
and EBNA-IgG antibodies were similar. The detection
rates were the lowest among children aged 8–24 monthsaged <8 months (n = 37)
n Percentage (%) Infection status
3 8.1 Primary infection
2 5.4 Primary infection
1 2.7 Primary infection
1 2.7 Primary infection
1 2.7 Primary infection
1 2.7 Primary infection
1 2.7 Past infection or maternal antibodies
10 27.0 Past infection or maternal antibodies
1 2.7 Past infection or maternal antibodies
2 5.4 Past infection or maternal antibodies
14 37.8 No infection
Table 2 EBV antibody combinations in EBV-positive patients aged ≥8 months (n = 280)
VCA-IgM Low affinity EA-IgG VCA-IgG EBNA-IgG N Percentage (%) Infection status
+ – – – – 7 2.5 Primary infection
+ – – + + 8 2.9 Primary infection
+ – – + – 1 0.4 Primary infection
+ – – – + 1 0.4 Primary infection
+ – + – – 1 0.4 Primary infection
+ – + – + 1 0.4 Primary infection
+ + – – – 6 2.1 Primary infection
+ + + – – 3 1.1 Primary infection
+ + + + – 1 0.4 Primary infection
+ + – + – 1 0.4 Primary infection
– + – – – 1 0.4 Primary infection
– + – + – 2 0.7 Primary infection
– + + + – 1 0.4 Primary infection
– – + – – 4 1.4 Primary infection
– – + + – 1 0.4 Primary infection
– – + + + 21 7.5 Primary infection
– – – + + 91 32.5 Past infection
– – – – + 4 1.4 Past infection
– – – + – 9 3.2 Orphaned VCA-IgG
– – – – – 116 41.4 No infection
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VCA-IgG and EBNA-IgG reached 60.5% and 62.8%, re-
spectively, in children aged ≥7 years. Patients aged 8–24
months had a lower detection rate of EBNA-IgG than
the other four groups (P < 0.001). Compared with the
age groups of 2–4 years, 4–7 years and ≥7 years, theFigure 1 The distribution of antibodies in EBV-positive patients. P < 0patients aged 8–24 months had the lowest detection
rates for VCA-IgG (P < 0.001).
EBV seropositivity rate by age
The patients were classified into five age groups. The pres-
ence of at least one positive result for VCA-IgM, VCA-.05 between * and **, and between # and ##.
Figure 2 EBV infection rates by age. P < 0.05 between * and **, and between # and ##.
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with EBV. The seropositive rate increased among children
aged 8–36 months and then plateaued among children
aged 36–108 months. For children aged ≥9 years, the posi-
tive rate was 84.2% as shown in the trend line (Figure 2).Table 3 The disease spectrum in EBV-positive children
Diagnosis Primary infection Pas
(n = 60) (n =
IM 24 (40.0%) 3 (3
Respiratory infection 25 (41.7%) 74 (
Kawasaki disease 2 (3.3%) 6 (6
ITP 1 (1.7%) 1 (1
Anaphylactic purpura 1 (1.7%) 1 (1
Ulcerative stomatitis 1 (1.7%)
Measles 1 (1.7%)
Asthma 1 (1.7%) 2 (2
JRA 1 (1.7%) 1 (1
Pulmonary tuberculosis 1 (1.7%) 1 (1
Herpangina 1 (1.7%) 1 (1
Hand-foot-mouth disease 1 (1.7%)
Summer fever 1 (1
GERD 1 (1
CMV infection 1 (1
Virus infection 1 (1




IM, infectious mononucleosis; ITP, idiopathic thrombocytopenic purpura; JRA, juvenThe disease spectrum of EBV infection
The EBV-related diseases were diverse (Table 3). The
most common disease caused by a primary infection
was respiratory tract infection (41.7%), followed by
IM (40.0%), Kawasaki disease, anaphylactic purpura,t infection Orphaned VCA-IgG No infection
95) (n = 9) (n = 116)
.2%) 1 (14.3%) 5 (4.3%)

















ile rheumatoid arthritis; GERD, gastroesophageal reflux disease.
Table 4 The distribution of age in EBV-positive patients (age ≥8 months)
Infection status Age (months)
8–11 12–23 24–35 36–59 ≥60
Primary infection (n = 60) 6 (21.4%) 13 (26.0%) 13 (24.5%) 13 (18.6%) 15 (19.0%)
Past infection (n = 95) 1 (3.6%)** 7 (14.0%)## 19 (35.9%)* 31 (44.3%)*# 37 (46.8%)*#
Orphaned VCA-IgG (n = 9) 1 (3.6%) 2 (4.0%) 2 (3.8%) 2 (2.9%) 2 (2.5%)
No infection (n = 116) 20 (71.4%)** 28 (56.0%) 19 (35.9%)* 24 (34.3%)* 25 (31.7%)*
Total 28 50 53 70 79
P < 0.05 between * and **, and between # and ##.
Table 6 Features in patients with an EBV primary
infection
Clinical features Primary infection
IM (n = 24) Non-IM (n = 36)
Age (months) 47.8 ± 38.8 41.8 ± 32.3
Male/female patients 11/13 17/19
Length of stay (days) 11.0 ± 2.7* 9.1 ± 4.1
Fever 23 (95.8%) 31 (86.1%)
Cough 12 (50.0%)* 30 (83.3%)
Rash 4 (16.7%) 14 (38.9%)
Lymphadenopathy 20 (83.3%)* 11 (30. 6%)
Pharyngitis 23 (95.8%)* 26 (72.2%)
Palatal petechiae 13 (54.2%)* 3 (8.3%)
Abnormal chest X ray 6/7 (85.7%)* 7/20 (35.0%)
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asthma. Seven of the nine patients presenting with
orphaned VCA-IgG were diagnosed with a respiratory
tract infection.
EBV primary/past infections and clinical features
To analyze the clinical features of EBV infection by age,
patients aged ≥8 months were classified into four groups:
60 had a primary EBV infection, 95 had a past infection,
nine had orphaned VCA-IgG and 116 were uninfected.
The distribution in these four groups by age is shown in
Table 4. The age group of 1–2 years had the highest detec-
tion rate for a primary EBV infection. The incidence of
past infection increased gradually with age from 3.6% to
46.8%, and the patients aged 8–12 months had a lower in-
cidence than the other three groups (P < 0.001) [Table 5].
These results indicate that EBV primary infection could
be detected in all age groups.
There were no differences between these age groups
in clinical features, but the mean hospital stay in the
primary-infected group was longer than in the past-
infected group (P < 0.001). The age distribution of chil-
dren with a primary EBV infection is shown in Table 6.
The detection rate of IM was highest among children aged
2–3 years. The clinical features in patients with a primary
EBV infection divided into those with and without IM are
listed in Table 7. Compared with the non-IM group, the
IM group with a primary EBV infection had more fre-
quent presentations of lymphadenopathy, pharyngitis, pal-
atal petechiae, abnormal chest X rays, hepatomegaly and
splenomegaly, an atypical lymphocyte count >10% and ab-
normal liver function. Patients without IM were classified






IM (n = 24) 7 (25.0%) 7 (53.9%) 10 (35.7%)
Non-IM (n = 45) 21 (75.0%) 6 (46.1%) 18 (64.3%)
Total 28 13 28had a past infection and 111 were uninfected (Table 7).
Rash was more frequent in children with a primary HBV
infection than in the other two groups (P < 0.01), but they
had a lower rate of abnormal chest X rays (P < 0.001).
Clinical features of different antibody combinations
To understand the implication of different antibody
combinations, five patterns were compared: group A
[VCA-IgM+, VCA-IgG– and EBNA-IgG–]; group B
[VCA-IgM+, VCA-IgG+ and EBNA-IgG+]; group C
[VCA-IgM–, VCA-IgG+ and EBNA-IgG–]; group D
[VCA-IgM–, VCA-IgG+ and EBNA-IgG+]; and group E
[VCA-IgM–, VCA-IgG– and EBNA-IgG–]. The symp-
toms and physical signs seemed to be most severe in the
patients of group A, especially an atypical lymphocyteHepatomegaly 11 (45.8%)* 0 (0.0%)
Splenomegaly 8 (33.3%)* 0 (0.0%)
ALC >10% 17/23 (73.9%)* 3/21 (14.3%)
Elevated ESR 11/20 (55.0%) 10/21 (47.6%)
Elevated CRP 9/19 (47.4%) 10/21 (47.6%)
ALF 13/18 (72.2%)* 4/18 (22.2%)
IM, infectious mononucleosis; Non-IM, patients without IM; ALC, atypical
lymphocytes; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein;
ALF, abnormal liver function (alanine aminotransferase or aspartate
aminotransferase levels >46 U/L). *P < 0.05 versus the non-IM group.
Table 7 Features in patients not diagnosed with IM
Clinical features Primary infection(n = 36) Past infection(n = 92) No infection(n = 111)
Age (months) 41.8 ± 32.3* 60.3 ± 37.7** 37.7 ± 29.5*
Male/female patients 17/19 57/35 74/37
Length of stay (days) 9.1 ± 4.1 7.8 ± 2.5* 8.9 ± 3.9
Fever 31 (86.1%) 83 (90.2%) 97 (87.4%)
Cough 30 (83.3%) 65 (70.6%) 85 (76.6%)
Rash 14 (38.9%)** 17 (18.5%)* 16 (14.4%)*
Lymphadenopathy 11 (30.6%) 33 (35.9%) 29 (1.8%)*
Pharyngitis 26 (72.2%) 74 (80.4%) 79 (71.2%)
Palatal petechiae 3 (8.3%) 16 (17.4) 20 (18.0%)
Abnormal chest X ray 7/20 (35.0%)** 40/46 (87.0%)* 49/61 (80.3%)*
Hepatomegaly 5 (5.4%) 7 (6.3%)
Splenomegaly 0 (0.0%) 3 (3.3%) 1 (0.9%)
ALC >10% 3/21 (14.3%) 9/51 (17.7%) 13/70 (18.6%)
Elevated ESR 10/21 (47.6%) 35/67 (53.2%) 30/63 (47.6%)
Elevated CRP 10/21 (47.6%) 33/68 (48.5%) 42/73 (57.5%)
ALF 4/18 (22.2%) 3/24 (12.5%) 12/33 (36.4%)
IM, infectious mononucleosis; Non-IM, patients without IM; ALC, atypical lymphocytes; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALF,
abnormal liver function (alanine aminotransferase or aspartate aminotransferase levels >46 U/L). P < 0.05 between * and **.
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boratory results in groups B and C were not more ser-
ious than in groups D or E. The pattern of group C
[VCA-IgM–, VCA-IgG+ and EBNA-IgG–] did not have
any specific clinical features (Table 8).Table 8 Clinical features of different antibody combinations i
Clinical features A (n = 17) B (n = 8)
Length of stay (days) 10.5 ± 2.9* 10.4 ± 4.9
Fever 17 (100.0%) 8 (100.0%)
Cough 9 (52.9%) 8 (100.0%)
Rash 4 (23.5%) 4 (50.0%)
Lymphadenopathy 11 (64.7%)** 6 (75.0%)
Pharyngitis 16 (94.1%) 7 (87.5%)
Palatal petechiae 9 (52.9%)** 2 (25.0%)
Abnormal chest X ray 8/9 (88.9%) 2/2 (100.0%)
Bronchitis (X ray) 3/9 (33.3%) 1/2 (50.0%)
Pneumonia (X ray) 5/9 (55.6%) 1/2 (50.0%)
Hepatomegaly 5 (29.4%) 2 (25.0%)
Splenomegaly 4 (23.5%) 0 (0.0%)
ALC >10% 12/15 (80.0%)** 0/6 (0.0%)*
Elevated ESR 8/14 (57.1%) 5/6 (83.3%)
Elevated CRP 4/13 (30.8%) 5/6 (83.3%)
ALF 9/13 (69.2%) 1/4 (25.0%)
A: patients with the antibody combination of [VCA-IgM+, VCA-IgG– and EBNA-IgG–]
EBNA-IgG+]. C: patients with the antibody combination of [VCA-IgM–, VCA-IgG+ and
IgG+ and EBNA-IgG+]. E: patients with the antibody combination of [VCA-IgM–, VCA
protein; ALC, atypical lymphocytes; ALF, abnormal liver function (alanine aminotran
and **.Discussion
We found that EBV was a common pathogen in these
Chinese children with respiratory tract infections and that
those aged 8–36 months had the highest risk of a primary
EBV infection. The determination of immunoglobulinsn EBV-positive patients (age ≥8 months)
C (n = 13) D (n = 112) E (n = 121)
9.0 ± 4.5 8.0 ± 2.9* 9.1 ± 4.0
12 (92.3%) 100 (89.3%) 106 (87.6%)
12 (92.3%) 79 (70.5%) 90 (74.4%)
0 (0.0%) 23 (20.5%) 19 (15.7%)
5 (38.5%) 41 (36.6%) 35 (28.9%)*
10 (76.9%) 89 (79.5%) 87 (71.9%)
5 (38.5%) 20 (17.9%)* 24 (19.8%)
3/5 (60.0%) 50/57 (87.7%) 53/65 (81.5%)
2/5 (40.0%) 32/57 (56.1%) 25/65 (38.5%)
1/5 (20.0%) 18/57 (31.6%) 28/65 (43.1%)
3 (23.1%) 7 (6.3%) 11 (9.1%)
1 (7.7%) 7 (6.3%) 5 (4.1%)
4/8 (50.0%) 14/66 (21.2%)* 18/77 (23.4%)*
2/10 (20.0%) 43/81 (53.1%) 31/66 (47.0%)
5/9 (55.6%) 42/83 (50.6%) 43/76 (56.6%)
2/6 (33.3%) 9/36 (25.0%) 15/38 (39.5%)
. B: patients with the antibody combination of [VCA-IgM+, VCA-IgG+ and
EBNA-IgG–]. D: patients with the antibody combination of [VCA-IgM–, VCA-
-IgG– and EBNA-IgG–]. ESR, erythrocyte sedimentation rate; CRP, C-reactive
sferase or aspartate aminotransferase levels >46 U/L). P < 0.05 between *
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pediatric patients [15,17]. VCA-IgM is generally designated
as an indicator of recent primary infection. VCA and EBNA
cause lifelong persistent IgG titers. The avidity of VCA-IgG
antibodies detected is low in samples from patients with re-
cent EBV infections and high in patients with a past infec-
tion or reactivation [10,17]. The combination of negative
EBNA-IgG and low-avidity VCA-IgG has given a sensitivity
and specificity of 100% [4].
In the present study, there were no differences between
the age groups in the detection rates for VCA-IgM, EA-
IgG and low-affinity VCA-IgG. The detection rates were
the lowest among those aged 8–24 months and increased
gradually with age. These two antibodies are the most fre-
quent in this age group because of the persistence of ma-
ternal antibodies in children aged <8 months; after the
maternal antibodies disappear, the infection rate increases
gradually. Most maternal antibodies disappear at 4
months of age and are no longer detectable at 8 months
[11]. To exclude the impact of maternal antibodies,
patients were divided into two groups, with 8 months as
the cutoff. Five patients had the combination of VCA-IgM
+ with low-affinity VCA-IgG–, three of whom presented
with a primary cytomegalovirus (CMV) infection. This is
known to produce a false-positive result for VCA-IgM
[18], so given the protective role played by maternal anti-
bodies, we surmise that the positive result for VCA-IgM
in these patients was induced by the CMV infection. The
youngest infant with a primary EBV infection having the
pattern of [VCA-IgM+, low affinity VCA-IgG+, EBNA-
IgG+, VCA-IgG– and EA-IgG–] was only 1 month old,
and this was probably caused by an intrauterine or intra-
partum infection. Previous studies have shown that EBV
might be present in cervical secretions, and EBV seems to
be able to cross the placenta and to cause placental infec-
tions manifested by deciduitis and villitis [19].
The presence of VCA-IgG in the absence of VCA-IgM
and EBNA-IgG antibodies makes classifying EBV infec-
tion more difficult. This serological picture can be seen
in cases of past infection with EBNA-IgG showing loss
or nonappearance of these antibodies, or in patients with
primary EBV infections with the early disappearance or
delayed onset of production of VCA-IgM. In this series,
13 patients (4.64%) were diagnosed with orphan VCA-
IgG+. A study in 2009 found that the prevalence of the
[VCA-IgG+, VCA IgM– and EBNA-1-IgG–] serological
combination in children aged 1–10 years was 4.5%, and
it was associated mainly with acute infection [20,21]. In
the present study, patients with this serological pattern
seemed to have more severe symptoms, physical signs
and adverse laboratory results, especially an atypical
lymphocyte count of >10% compared with the pattern
[VCA-IgM–, VCA-IgG+ and EBNA-IgG–]. This could
have been associated with an EBV primary infectioncausing IM. EBV-associated IM occurred in all age
groups, with a peak incidence at 2–4 years in Hong
Kong [22], which is similar to the result of our study
(a peak incidence at 2–3 years).
The disease spectrum associated with a primary EBV
infection is very diverse. In most studies published out-
side China, about 50% of children with an EBV infection
develop IM [23], and the proportion of IM seen in our
study was similar (40%) and much higher than other
studies in China [24,25], where the proportion of IM in
the disease spectrum was only 17.9%. However, our
results show that EBV mainly caused respiratory tract
infections. These results suggest that EBV is a common
pathogen in respiratory tract infections as well as in IM.
EBV seropositivity among children has a geographic
variation: the age of primary infection is earlier in Asia
and other developing countries than in Western coun-
tries. The infection rate of 2-year-old children exceeded
60.7% in Hong Kong in 2001 [12]. In our study, the posi-
tive rate among children aged 2–3 years was 64.5%.
However, it was 84.2% among those aged ≥9 years, so
there was no obvious decline in the infection rate.
Conclusions
These Chinese infants aged <8 months could be infected by
EBV and about 84% of children aged ≥9 years had sero-
logical evidence of EBV infection. In addition to causing
IM, EBV was also a common pathogen in children with re-
spiratory tract infections. The detection rate of EBV-related
IM peaked in patients aged 2–3 years.
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